These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 3831175)

  • 1. [Natural killer activity in brain tumor patients treated with interferon and steroid].
    Nakagawa Y; Ibayashi N; Ueda S; Hirakawa K; Amagai T; Imanishi J; Fukuma S
    Nihon Gan Chiryo Gakkai Shi; 1985 Dec; 20(10):2305-13. PubMed ID: 3831175
    [No Abstract]   [Full Text] [Related]  

  • 2. Local administration of interferon for malignant brain tumors.
    Nakagawa Y; Hirakawa K; Ueda S; Suzuki K; Fukuma S; Kishida T; Imanishi J; Amagai T
    Cancer Treat Rep; 1983 Sep; 67(9):833-5. PubMed ID: 6688376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Induction of LAK cells and CTL in patients with brain tumor and research of its clinical application].
    Moriki A
    Nihon Geka Hokan; 1989 Jan; 58(1):107-18. PubMed ID: 2802908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impairment of natural killer (NK) function in carriers and patients with thalassemia major.
    Goicoa MA; Estevez ME; Ballart IJ; Diez RA; Peñalver JA; de Miani SA; Sen L
    Nouv Rev Fr Hematol (1978); 1986; 28(2):75-9. PubMed ID: 3737398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interferon-producing and cytotoxic activity of natural killer cells in multiple sclerosis patients].
    Sorokin AM; Koval'chuk LV; Tunkel' OI; Cheknev SB
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1987; 87(2):211-5. PubMed ID: 2437743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cell activity in patients with multiple sclerosis given alpha interferon.
    Rice GP; Casali P; Merigan TC; Oldstone MB
    Ann Neurol; 1983 Sep; 14(3):333-8. PubMed ID: 6638954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon.
    Lotzová E; Savary CA; Quesada JR; Gutterman JU; Hersh EM
    J Natl Cancer Inst; 1983 Nov; 71(5):903-10. PubMed ID: 6580490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysis of fresh leukemic blasts by interferon-activated human natural killer cells.
    Pattengale PK; Sundstrom C; Yu AL; Levine A
    Nat Immun Cell Growth Regul; 1983-1984; 3(4):165-80. PubMed ID: 6597341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Activity of the natural killer cells in the peripheral blood of patients with brain tumors].
    Lisianyĭ NI; Markova OV; Zhmareva EN
    Eksp Onkol; 1988; 10(3):57-9. PubMed ID: 3409835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The role of adherent cells in supporting natural cytotoxicity reactions].
    Sorokin AM; Chenëv SB; Koval'chuk LV
    Biull Eksp Biol Med; 1989 Sep; 108(9):322-5. PubMed ID: 2611391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basic and interferon-augmented natural killer (NK) cell activity in psoriasis.
    Jansén CT; Viander M
    Acta Derm Venereol; 1983; 63(5):384-7. PubMed ID: 6197835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of interferon on malignant brain tumor].
    Wakabayashi T; Yoshida J; Kobayashi T; Kageyama N; Kanzaki M
    Gan To Kagaku Ryoho; 1982 Aug; 9(8):1400-6. PubMed ID: 7184455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Enhancement of NK-activity and LAK-activity in combination therapy with interferon-alpha in a child with neuroblastoma].
    Fukushima K; Tanaka K; Matsumoto Y; Nishikawa K; Hoshika T; Kohno Y; Okada T; Shiraki K
    Gan To Kagaku Ryoho; 1987 Aug; 14(8):2597-9. PubMed ID: 3619468
    [No Abstract]   [Full Text] [Related]  

  • 14. Direct suppression of natural killer activity in human peripheral blood leukocyte cultures by glucocorticoids and its modulation by interferon.
    Holbrook NJ; Cox WI; Horner HC
    Cancer Res; 1983 Sep; 43(9):4019-25. PubMed ID: 6871844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive immunotherapy of malignant diseases with IL-2-activated lymphocytes.
    Kimoto Y; Taguchi T
    Biken J; 1987 Jun; 30(2):29-38. PubMed ID: 3501954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon enhanced natural killer function in Hodgkin's disease.
    Levy S; Reins F; Aleksijevic A; Giron C; Oberling F; Mayer S; Lang JM
    Nouv Rev Fr Hematol (1978); 1986; 28(5):323-5. PubMed ID: 3808943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer activity and antibody-dependent cellular cytotoxicity in patients with non-Hodgkin's lymphoma.
    Metha BA; Advani SH; Nadkarni SJ
    Neoplasma; 1988; 35(1):61-8. PubMed ID: 3352838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of natural killer cell function during interferon-alpha treatment of patients with condyloma acuminatum is predictive of clinical response.
    Tyring SK; Cauda R; Ghanta V; Hiramoto R
    J Biol Regul Homeost Agents; 1988; 2(2):63-6. PubMed ID: 3188977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of interferon on clinico-laboratory indicators in patients with acute viral hepatitis B].
    Pokrovskiĭ VI; Zmyzgova AV; Matveeva SM; Saltykov VP; Soibnazarov ISh
    Ter Arkh; 1986; 58(10):29-32. PubMed ID: 3798344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in immune function in patients receiving natural leukocyte interferon.
    Maluish AE; Ortaldo JR; Sherwin SA; Oldham RK; Herberman RB
    J Biol Response Mod; 1983; 2(5):418-27. PubMed ID: 6644346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.